Corient Private Wealth’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
Other funds holding GALT
Corient Private Wealth's GALT Position: Q3 2026 in Review
Corient Private Wealth opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 541,797 shares worth $2.1M. The stake represents ﹤0.01% of the portfolio and ranks #1595 among its holdings.
91 funds tracked by Wall St. Rank hold GALT as of Q3 2026.
- Corient Private Wealth held 541,797 shares of Galectin Therapeutics worth $2.1M as of Q3 2026.
- Galectin Therapeutics was a new Corient Private Wealth position in Q3 2026.
- Galectin Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q3 2026, its #1595 holding.
- 91 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.
Based on Corient Private Wealth's 13F filing for Q3 2026, filed 16 Nov 2026.